PL3823617T3 - Enancjomerycznie oczyszczony agonista gper do zastosowania w leczeniu stanów chorobowych i schorzeń - Google Patents
Enancjomerycznie oczyszczony agonista gper do zastosowania w leczeniu stanów chorobowych i schorzeńInfo
- Publication number
- PL3823617T3 PL3823617T3 PL19842049.9T PL19842049T PL3823617T3 PL 3823617 T3 PL3823617 T3 PL 3823617T3 PL 19842049 T PL19842049 T PL 19842049T PL 3823617 T3 PL3823617 T3 PL 3823617T3
- Authority
- PL
- Poland
- Prior art keywords
- conditions
- disease states
- treating disease
- enantiomerically purified
- gper agonist
- Prior art date
Links
- 101150007919 Gper1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701726P | 2018-07-21 | 2018-07-21 | |
| PCT/US2019/042827 WO2020023391A1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3823617T3 true PL3823617T3 (pl) | 2024-08-12 |
Family
ID=69160978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19842049.9T PL3823617T3 (pl) | 2018-07-21 | 2019-07-22 | Enancjomerycznie oczyszczony agonista gper do zastosowania w leczeniu stanów chorobowych i schorzeń |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20200024262A1 (enExample) |
| EP (2) | EP3823617B1 (enExample) |
| JP (2) | JP2021532148A (enExample) |
| KR (1) | KR20210049778A (enExample) |
| CN (1) | CN112469409B (enExample) |
| AU (1) | AU2019310029B2 (enExample) |
| BR (1) | BR112021001031A2 (enExample) |
| CA (1) | CA3107109A1 (enExample) |
| DK (1) | DK3823617T3 (enExample) |
| ES (1) | ES2980434T3 (enExample) |
| FI (1) | FI3823617T3 (enExample) |
| HR (1) | HRP20240661T1 (enExample) |
| HU (1) | HUE067185T2 (enExample) |
| IL (2) | IL312938A (enExample) |
| LT (1) | LT3823617T (enExample) |
| MX (2) | MX2021000809A (enExample) |
| NZ (1) | NZ771952A (enExample) |
| PL (1) | PL3823617T3 (enExample) |
| PT (1) | PT3823617T (enExample) |
| RS (1) | RS65599B1 (enExample) |
| SI (1) | SI3823617T1 (enExample) |
| SM (1) | SMT202400205T1 (enExample) |
| WO (1) | WO2020023391A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CA3214822A1 (en) * | 2021-04-08 | 2022-10-13 | Tina Garyantes | Oncologic variations associated with cancer and methods of treatment |
| JP2024522257A (ja) * | 2021-05-19 | 2024-06-12 | リネウス セラピューティクス インコーポレイテッド | 癌の治療のための診断方法および組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US251870A (en) * | 1882-01-03 | Automatic gate | ||
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| US7875721B2 (en) * | 2005-08-04 | 2011-01-25 | Stc.Unm | Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
| WO2008153945A2 (en) * | 2007-06-06 | 2008-12-18 | University Of South Florida | Nutraceutical co-crystal compositions |
| EP2635284B1 (en) * | 2010-11-01 | 2019-12-18 | Celgene CAR LLC | Heterocyclic compounds and uses thereof |
| US10251870B2 (en) * | 2015-03-06 | 2019-04-09 | Stc.Unm | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity |
| CN107613971A (zh) * | 2015-04-06 | 2018-01-19 | 宾夕法尼亚大学董事会 | 用于减少、或预防或逆转哺乳动物对象中皮肤色素沉着增加的组合物和方法 |
| CA3027705A1 (en) | 2016-06-17 | 2017-12-21 | The Trustees Of The University Of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
-
2019
- 2019-07-22 RS RS20240634A patent/RS65599B1/sr unknown
- 2019-07-22 PT PT198420499T patent/PT3823617T/pt unknown
- 2019-07-22 DK DK19842049.9T patent/DK3823617T3/da active
- 2019-07-22 IL IL312938A patent/IL312938A/en unknown
- 2019-07-22 ES ES19842049T patent/ES2980434T3/es active Active
- 2019-07-22 PL PL19842049.9T patent/PL3823617T3/pl unknown
- 2019-07-22 BR BR112021001031-9A patent/BR112021001031A2/pt unknown
- 2019-07-22 KR KR1020217002117A patent/KR20210049778A/ko not_active Ceased
- 2019-07-22 SM SM20240205T patent/SMT202400205T1/it unknown
- 2019-07-22 LT LTEPPCT/US2019/042827T patent/LT3823617T/lt unknown
- 2019-07-22 IL IL280283A patent/IL280283B2/en unknown
- 2019-07-22 EP EP19842049.9A patent/EP3823617B1/en active Active
- 2019-07-22 JP JP2021504360A patent/JP2021532148A/ja active Pending
- 2019-07-22 MX MX2021000809A patent/MX2021000809A/es unknown
- 2019-07-22 HU HUE19842049A patent/HUE067185T2/hu unknown
- 2019-07-22 FI FIEP19842049.9T patent/FI3823617T3/fi active
- 2019-07-22 CA CA3107109A patent/CA3107109A1/en active Pending
- 2019-07-22 CN CN201980048925.4A patent/CN112469409B/zh active Active
- 2019-07-22 NZ NZ771952A patent/NZ771952A/en unknown
- 2019-07-22 SI SI201930756T patent/SI3823617T1/sl unknown
- 2019-07-22 EP EP24161261.3A patent/EP4356913A3/en not_active Withdrawn
- 2019-07-22 WO PCT/US2019/042827 patent/WO2020023391A1/en not_active Ceased
- 2019-07-22 AU AU2019310029A patent/AU2019310029B2/en active Active
- 2019-07-22 US US16/518,516 patent/US20200024262A1/en not_active Abandoned
- 2019-07-22 HR HRP20240661TT patent/HRP20240661T1/hr unknown
- 2019-11-13 US US16/682,821 patent/US10934277B2/en active Active
-
2021
- 2021-01-20 MX MX2024008188A patent/MX2024008188A/es unknown
- 2021-02-25 US US17/184,870 patent/US11760749B2/en active Active
- 2021-05-24 US US17/328,590 patent/US20220089576A1/en not_active Abandoned
-
2023
- 2023-08-03 US US18/364,690 patent/US20230382896A1/en not_active Abandoned
-
2024
- 2024-05-29 JP JP2024087006A patent/JP2024119868A/ja active Pending
- 2024-06-24 US US18/752,146 patent/US20250171421A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285649A (en) | Azepino-indoles and other heterocyclics for the treatment of brain disorders | |
| IL273820A (en) | Systems and methods to ensure data security of treatment methods for diseases and disorders that use digital therapies | |
| ZA202106620B (en) | Subscription to changes in policy data | |
| SG11202013239RA (en) | Composition and method for treating pain | |
| IL271503A (en) | Preparations and treatments for sleep disorders | |
| PL3407889T3 (pl) | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego | |
| IL276247A (en) | Methods and materials for the treatment of sleep apnea | |
| IL277182A (en) | Compositions and methods for treating Parkinson's disease | |
| IL280283A (en) | An enantiomerically pure GPER agonist for use in the treatment of disease states and conditions | |
| PL3362449T3 (pl) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową | |
| ZA201807653B (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| SG11202105533YA (en) | Decarboxylase inhibitors for treating parkinson's disease | |
| IL275875A (en) | Treatment and prevention of sleep disorders | |
| IL275935A (en) | Its use and its derivative | |
| SG11202001833WA (en) | Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions | |
| ZA202002526B (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| GB201807611D0 (en) | Methods for assessing and treating complement-related disorders | |
| GB201902790D0 (en) | Methods for assessing and treating complement-related disorders | |
| SG10201408115SA (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | |
| GB201918539D0 (en) | Compounds for use in treatment and prophylaxis | |
| HK40058491A (en) | New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions | |
| SG11202101196TA (en) | Behavioural treatment | |
| SG11202104661WA (en) | Composition and method for aiding sleep | |
| GB201801178D0 (en) | Method and use | |
| GB201801180D0 (en) | Method and use |